Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
Anal cancer is a malignant tumor occurring in the anal canal and anal margin, predominantly squamous cell carcinoma. Its pathogenesis is closely related to human papillomavirus (HPV) infection and HIV infection. Although a rare tumor, its incidence has been rising in recent years, particularly among middle-aged and elderly women and immunocompromised individuals. Early symptoms of anal cancer are atypical and often mistaken for hemorrhoids or anal fissures, making public awareness crucial.
The incidence of anal cancer is slightly higher in Europe and the U.S., particularly among women in the U.S. and U.K., where it has shown a slow upward trend. In Asia, the overall incidence remains relatively low, but recent years have seen increasing cases among younger populations in Southeast Asian countries such as Thailand and the Philippines.
1. Local tissue invasion causing chronic pain
Anal cancer may gradually invade the anal sphincter and adjacent structures, leading to persistent pain, difficulty with defecation, and even intestinal obstruction, severely affecting quality of life.
2. High risk of misdiagnosis delaying treatment
Because early symptoms resemble common anal conditions such as fissures or hemorrhoids, patients often ignore them or are misdiagnosed, missing the optimal window for intervention.
3. Potential metastasis to lymph nodes and distant organs
If left untreated, anal cancer can spread via the lymphatic system to pelvic or inguinal lymph nodes and even metastasize to the lungs or liver, significantly worsening prognosis.
4. Psychological and social distress
Due to the sensitive site of the disease, patients often feel embarrassment and shame, reluctant to seek medical attention, which impacts social and family relationships.
Immune reconstruction cell therapy activates the patient’s own immune system to recognize and attack cancer cells, showing significant advantages in anal cancer treatment. This technique targets tumor-associated antigens to selectively eliminate abnormal cells and is suitable for patients with local recurrence or poor tolerance to chemoradiotherapy. It may also serve as an adjuvant therapy to improve postoperative control.
In practice, patients undergoing traditional treatments such as surgery, radiotherapy, or chemotherapy often face immune dysfunction, increased infection risks, and slow recovery. To better support patients through treatment, improve tolerance, and enhance quality of life, phased immune reconstruction plans should be scientifically developed for different treatment cycles.
● Short-term plan: Rapidly enhance immunity through immune cell reinfusion, boosting the effectiveness of anti-cancer treatment.
● Mid-term plan: Reduce the side effects of traditional treatments, promote physical recovery, and complete standardized treatment courses.
● Long-term plan: Enhance overall immunity through immune cell reconstruction, gut immune reconstruction, elemental immune reconstruction, and immune nutrition reconstruction, thereby improving quality of life and prolonging survival.
1. Concurrent chemoradiotherapy
Concurrent chemotherapy and radiotherapy have become the standard treatment for locally advanced anal cancer. This approach effectively shrinks tumors, eliminates micro-lesions, preserves anal function, and significantly increases the anal preservation rate.
2. Local surgical treatment
For early-stage or localized recurrent lesions, local excision can remove the tumor. For patients unresponsive to chemoradiotherapy, abdominoperineal resection remains a necessary option.
3. Minimally invasive treatment options
In recent years, minimally invasive techniques such as endoscopic excision, image-guided microwave ablation, and particle implantation have been applied to select early-stage patients. These approaches cause less trauma, enable faster recovery, and provide new possibilities for preserving anal function.
4. Targeted and antiviral therapies
Targeted therapies are under research, particularly interventions against HPV-related proteins, which represent a new direction. Additionally, antiviral treatments aimed at controlling HPV infection may help prevent disease progression or recurrence.
Although anal cancer is a low-incidence tumor, its harms cannot be underestimated. Given its easily overlooked early symptoms, heightened vigilance is required. Experts at United Life International Medical Center emphasize that early intervention combined with multimodal therapies helps improve prognosis and quality of life.
